Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
AbbVie Inc. pages available for free this week:
- Common-Size Income Statement
- Analysis of Solvency Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Capital Asset Pricing Model (CAPM)
- Return on Assets (ROA) since 2012
- Debt to Equity since 2012
- Total Asset Turnover since 2012
- Price to Book Value (P/BV) since 2012
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to AbbVie Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Long-term Activity Ratios (Summary)
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
- Net Fixed Asset Turnover
- The net fixed asset turnover ratio shows a consistent upward trend from 8.73 in March 2020 to a peak around 11.82 in December 2022. Following this peak, a gradual decline is observed, decreasing to 10.95 by March 2025. This suggests initially improving efficiency in utilizing fixed assets to generate sales, followed by a slight reduction in efficiency in later periods.
- Total Asset Turnover
- Total asset turnover begins at 0.30 in March 2020 and steadily increases to 0.42 by December 2023, indicating an improvement in overall asset utilization to generate sales. However, a slight decrease is noted during the mid-2024 period, dropping to 0.37 in June 2024. The ratio recovers again towards the end of the series, reaching 0.42 by March 2025. Overall, the trend reflects moderate enhancement in asset efficiency with minor fluctuations.
- Equity Turnover
- The equity turnover ratio exhibits substantial volatility and a significant upward trajectory. Starting at 3.5 in March 2020, it fluctuates through 2021 and early 2022, maintaining approximate values between 3.36 and 4.56. Beginning in late 2023, a marked increase occurs, peaking sharply at 40.4 by March 2025. This dramatic rise points to an exceptional increase in sales relative to shareholders' equity, possibly driven by changes in capital structure, increases in leverage, or significant growth in sales with relatively stable equity.
Net Fixed Asset Turnover
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net revenues | ||||||||||||||||||||||||||||
Property and equipment, net | ||||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Net fixed asset turnover1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Net Fixed Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Net fixed asset turnover
= (Net revenuesQ1 2025
+ Net revenuesQ4 2024
+ Net revenuesQ3 2024
+ Net revenuesQ2 2024)
÷ Property and equipment, net
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Revenues
- The net revenues exhibit a generally cyclical pattern with noticeable fluctuations across the examined quarters. Starting at 8,619 million USD in March 2020, there is a significant increase reaching a peak of 14,886 million USD by December 2021. Post this peak, revenues decline to a low of 12,225 million USD in March 2023, followed by a recovery trend towards 15,102 million USD in December 2024. The revenues again decrease to 13,343 million USD by March 2025. The trend suggests seasonal or periodic factors impacting revenue, showing resilience with recurring recoveries after downturns.
- Property and Equipment, Net
- The net value of property and equipment remains relatively stable with minor fluctuations from 2,961 million USD in March 2020, rising sharply to 4,908 million USD by June 2020, and then maintaining a narrow range between approximately 4,893 million USD and 5,237 million USD from September 2020 through March 2025. This stability indicates limited new capital expenditures or disposals in fixed assets, reflecting a steady asset base during the periods surveyed.
- Net Fixed Asset Turnover
- Starting in September 2020, the net fixed asset turnover ratio shows an ascending trend from 8.73 to a peak of 11.82 in December 2022. After that peak, there is a gradual decline to around 10.95 by September 2024, followed by minor fluctuations around that value through March 2025. The initial rising ratio indicates improved efficiency in using fixed assets to generate revenue, whereas the later stabilization and slight decline could suggest a maturing asset usage or relatively slower sales growth compared to asset base.
- Overall Insights
- The data reflects a company navigating periods of growth and contraction in revenue, with a relatively consistent investment in property and equipment. The improved fixed asset turnover up to late 2022 points to increased operational efficiency, though there is some deceleration in this trend afterward. The cyclical revenue pattern accompanied by steady fixed assets implies that revenue volatility is likely influenced by external factors rather than major changes in capital investment.
Total Asset Turnover
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net revenues | ||||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Total asset turnover1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Total Asset Turnover, Competitors2 | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Total asset turnover
= (Net revenuesQ1 2025
+ Net revenuesQ4 2024
+ Net revenuesQ3 2024
+ Net revenuesQ2 2024)
÷ Total assets
= ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Revenues
-
Net revenues exhibited a generally cyclical pattern with notable fluctuations across the reported quarters. From March 31, 2020, to December 31, 2020, revenues increased significantly from $8,619 million to $13,858 million, indicating strong growth during this period. The upward trend continued into 2021, peaking at $14,886 million in December. However, starting in early 2022, net revenues experienced a decline, falling to $12,225 million by March 31, 2023. Subsequent quarters through March 31, 2025, show a pattern of recovery and volatility, with revenues oscillating between approximately $12,000 million and $15,102 million. The data reveals recurrent seasonal or cyclical trends, with peaks often occurring in the last quarter of each year followed by declines in the first quarter of the following years. Overall, despite these fluctuations, net revenues demonstrate resilience and a capacity for recovery after downturns.
- Total Assets
-
Total assets started at $91,199 million at the beginning of the period and experienced a substantial increase, reaching a peak of $150,565 million by December 31, 2020. Following this peak, a gradual decline occurred with minor fluctuations, bringing total assets down to about $134,504 million by December 31, 2023. A notable increase was observed again around March to June 2024, rising back to approximately $148,874 million. Subsequently, asset values declined again toward early 2025, settling near $136,165 million by March 31, 2025. This pattern suggests considerable asset revaluation or structural changes within the company’s asset base, characterized by a significant growth phase in 2020, followed by moderate contraction and intermittent rebounds.
- Total Asset Turnover
-
The total asset turnover ratio was not available for the early periods but, from September 30, 2020, it showed a consistent upward trend. Starting at 0.30, the ratio climbed steadily to 0.42 by December 31, 2022. Following this peak, the ratio slightly declined and fluctuated around 0.40 to 0.42 through March 31, 2025. The increasing trend in asset turnover during the majority of the period suggests improving efficiency in using assets to generate sales. The slight recent variability may imply adjustments in operational efficiency or shifts in asset structure relative to revenues.
- Summary
-
The overall financial data indicates a period of significant growth in revenues and asset base up to late 2020, followed by short-term declines and fluctuations through early 2023. Net revenues and total assets both reveal cyclical patterns, with evidence of recovery phases after downturns. The asset utilization, as measured by total asset turnover, generally improved throughout the period, indicating enhanced operational efficiency despite some recent variability. Together, these trends suggest the company navigated through changing market conditions with periods of both expansion and consolidation. Continued monitoring of cyclical fluctuations and efficiency metrics will be important for assessing future performance stability.
Equity Turnover
Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||||
Net revenues | ||||||||||||||||||||||||||||
Stockholders’ equity (deficit) | ||||||||||||||||||||||||||||
Long-term Activity Ratio | ||||||||||||||||||||||||||||
Equity turnover1 | ||||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||||
Equity Turnover, Competitors2 | ||||||||||||||||||||||||||||
Amgen Inc. | ||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||||
Danaher Corp. | ||||||||||||||||||||||||||||
Eli Lilly & Co. | ||||||||||||||||||||||||||||
Gilead Sciences Inc. | ||||||||||||||||||||||||||||
Johnson & Johnson | ||||||||||||||||||||||||||||
Merck & Co. Inc. | ||||||||||||||||||||||||||||
Pfizer Inc. | ||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||||
Vertex Pharmaceuticals Inc. |
Based on: 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q1 2025 Calculation
Equity turnover
= (Net revenuesQ1 2025
+ Net revenuesQ4 2024
+ Net revenuesQ3 2024
+ Net revenuesQ2 2024)
÷ Stockholders’ equity (deficit)
= ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends across the quarterly periods under review.
- Net Revenues
- Net revenues demonstrated considerable variability, with fluctuations observed in almost every quarter. The period beginning March 31, 2020, started with revenues at 8,619 million US dollars, reaching a peak around December 31, 2020, at 13,858 million. This was followed by intermittent declines and recoveries through subsequent quarters. Notably, there was a downward trend around the March 31, 2023, period with revenues falling to 12,225 million, but revenues rebounded partially in following quarters, topping again near 15,102 million at December 31, 2024. However, by the latest quarter (March 31, 2025), revenues decreased to 13,343 million.
- Stockholders’ Equity (Deficit)
- The stockholders’ equity exhibited significant fluctuations and an overall declining trend over the examined periods. Initially, equity showed a negative position of -7,415 million US dollars at March 31, 2020. This transitioned rapidly to a positive value in the following quarters, peaking around 17,254 million at December 31, 2022. Subsequent quarters saw a gradual and then more pronounced reduction in equity, reaching a level of 1,420 million by March 31, 2025. This downward trajectory signals either distributions, losses, or other equity adjustments negatively impacting shareholder value over time.
- Equity Turnover
- Equity turnover ratios were not reported for the earliest quarters but begin at 3.5 and exhibit a strong upward trend throughout the dataset. Starting from 3.5 at the earliest reported point, the ratio steadily climbed to extremely high values, peaking at 40.4 by March 31, 2025. This sharp increase indicates intensifying use of equity to generate revenues, which may reflect either increasing operational efficiency or potentially enhanced financial leverage or risk.
In summary, net revenues showed cyclicality with peaks and troughs but generally maintained a broad range around 12 to 15 billion US dollars after 2021. Stockholders’ equity moved from negative to positive but then sharply declined in later years, suggesting increasing financial pressures or capital structure changes. Concurrently, the equity turnover ratio rose markedly, implying more aggressive asset deployment or leverage in relation to shareholder equity. These dynamics warrant attention to the company’s management of equity resources and revenue sustainability over the reported periods.